These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35386599)

  • 1. Polycystic Kidney Disease-Related Disease Burden in Adolescents With Autosomal Dominant Polycystic Kidney Disease: An International Qualitative Study.
    Oberdhan D; Schaefer F; Cole JC; Palsgrove AC; Dandurand A; Guay-Woodford L
    Kidney Med; 2022 Mar; 4(3):100415. PubMed ID: 35386599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caregiver Burden of Autosomal Dominant Polycystic Kidney Disease: A Qualitative Study.
    Oberdhan D; Palsgrove AC; Cole JC; Harris T
    Kidney Med; 2023 Feb; 5(2):100587. PubMed ID: 36686593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument.
    Oberdhan D; Cole JC; Krasa HB; Cheng R; Czerwiec FS; Hays RD; Chapman AB; Perrone RD
    Am J Kidney Dis; 2018 Feb; 71(2):225-235. PubMed ID: 29150246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Patient-Reported Outcomes Tool to Assess Pain and Discomfort in Autosomal Dominant Polycystic Kidney Disease.
    Oberdhan D; Cole JC; Atkinson MJ; Krasa HB; Davison SN; Perrone RD
    Clin J Am Soc Nephrol; 2023 Feb; 18(2):213-222. PubMed ID: 36754008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey.
    Cho Y; Rangan G; Logeman C; Ryu H; Sautenet B; Perrone RD; Nadeau-Fredette AC; Mustafa RA; Htay H; Chonchol M; Harris T; Gutman T; Craig JC; Ong ACM; Chapman A; Ahn C; Coolican H; Kao JT; Gansevoort RT; Torres V; Pei Y; Johnson DW; Viecelli AK; Teixeira-Pinto A; Howell M; Ju A; Manera KE; Tong A
    Am J Kidney Dis; 2020 Sep; 76(3):361-373. PubMed ID: 32359822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study.
    Miskulin DC; Abebe KZ; Chapman AB; Perrone RD; Steinman TI; Torres VE; Bae KT; Braun W; Winklhofer FT; Hogan MC; Rahbari-Oskoui F; Moore CG; Flessner MF; Schrier RW;
    Am J Kidney Dis; 2014 Feb; 63(2):214-26. PubMed ID: 24183837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disconnect in Assessments of Autosomal Dominant Polycystic Kidney Disease Burden Between Patients and Physicians: A Survey Study.
    Sanon Aigbogun M; Oberdhan D; Doane MJ; Rooney J; Inyart BC; Pao CS; Denny AH
    Int J Nephrol Renovasc Dis; 2021; 14():105-115. PubMed ID: 33880055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review.
    Sautenet B; Cho Y; Gutman T; Rangan G; Ong A; Chapman AB; Ahn C; Coolican H; Tze-Wah Kao J; Fowler K; Gansevoort RT; Geneste C; Perrone RD; Harris T; Torres VE; Pei Y; Craig JC; Tong A;
    Am J Kidney Dis; 2020 Aug; 76(2):213-223. PubMed ID: 32171640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Standardised Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease.
    Cho Y; Sautenet B; Rangan G; Craig JC; Ong ACM; Chapman A; Ahn C; Chen D; Coolican H; Kao JT; Gansevoort R; Perrone R; Harris T; Torres V; Pei Y; Kerr PG; Ryan J; Gutman T; Howell M; Ju A; Manera KE; Teixeira-Pinto A; Hamiwka LA; Tong A
    Trials; 2017 Nov; 18(1):560. PubMed ID: 29169385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAPID-ADPKD (Retrospective epidemiological study of Asia-Pacific patients with rapId Disease progression of Autosomal Dominant Polycystic Kidney Disease): study protocol for a multinational, retrospective cohort study.
    Ryu H; Park HC; Oh YK; Sangadi I; Wong A; Mei C; Ecder T; Wang AY; Kao TW; Huang JW; Rangan GK; Ahn C
    BMJ Open; 2020 Feb; 10(2):e034103. PubMed ID: 32034027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression.
    Neijenhuis MK; Kievit W; Perrone RD; Sloan JA; Erwin P; Murad MH; Gevers TJG; Hogan MC; Drenth JPH
    BMC Nephrol; 2017 May; 18(1):169. PubMed ID: 28545401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial.
    Schaefer F; Mekahli D; Emma F; Gilbert RD; Bockenhauer D; Cadnapaphornchai MA; Shi L; Dandurand A; Sikes K; Shoaf SE
    Eur J Pediatr; 2019 Jul; 178(7):1013-1021. PubMed ID: 31053954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of renal transcatheter arterial embolization on quality of life in patients with autosomal dominant polycystic kidney disease.
    Suwabe T; Ubara Y; Sekine A; Ueno T; Yamanouchi M; Hayami N; Hoshino J; Kawada M; Hiramatsu R; Hasegawa E; Sawa N; Takaichi K
    Nephrol Dial Transplant; 2017 Jul; 32(7):1176-1183. PubMed ID: 28873973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the Symptom Burden and Impact of Myasthenia Gravis from the Patient's Perspective: A Qualitative Study.
    Jackson K; Parthan A; Lauher-Charest M; Broderick L; Law N; Barnett C
    Neurol Ther; 2023 Feb; 12(1):107-128. PubMed ID: 36322146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD) Consensus Workshop.
    Cho Y; Tong A; Craig JC; Mustafa RA; Chapman A; Perrone RD; Ahn C; Fowler K; Torres V; Gansevoort RT; Ong ACM; Coolican H; Tze-Wah Kao J; Harris T; Gutman T; Shen JI; Viecelli AK; Johnson DW; Au E; El-Damanawi R; Logeman C; Ju A; Manera KE; Chonchol M; Odland D; Baron D; Pei Y; Sautenet B; Rastogi A; Sharma A; Rangan G;
    Am J Kidney Dis; 2021 Feb; 77(2):255-263. PubMed ID: 32771648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.
    Meijer E; Visser FW; van Aerts RMM; Blijdorp CJ; Casteleijn NF; D'Agnolo HMA; Dekker SEI; Drenth JPH; de Fijter JW; van Gastel MDA; Gevers TJ; Lantinga MA; Losekoot M; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Wetzels JF; Zietse R; Gansevoort RT;
    JAMA; 2018 Nov; 320(19):2010-2019. PubMed ID: 30422235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient Perspectives on ADPKD.
    Gittus M; Harris T; Ong AC
    Adv Kidney Dis Health; 2023 May; 30(3):294-302. PubMed ID: 37088530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial.
    Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Wetzels JF; Drenth JP
    Liver Int; 2015 May; 35(5):1607-14. PubMed ID: 25369108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypomagnesaemia is absent in children with autosomal dominant polycystic kidney disease.
    Seeman T; Fořtová M; Sopko B; Průša R; Pohl M; John U
    Ann Clin Biochem; 2019 Jan; 56(1):90-94. PubMed ID: 29874928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.